Literature DB >> 23857602

Estrogen receptor α regulates ATM Expression through miRNAs in breast cancer.

Xiaojing Guo1, Chunying Yang, Xiaolong Qian, Ting Lei, Yaqing Li, Haifa Shen, Li Fu, Bo Xu.   

Abstract

PURPOSE: Estrogen receptor α (ERα) is an essential element regulating mammary gland development and it contributes to breast cancer development and progression. Most of the ER-negative breast cancers display more aggressive clinical behaviors and are resistant to antiestrogen therapies. In addition, many ER-negative tumors show insensitivity to many chemotherapeutic drugs and radiotherapy, although mechanisms underlying this phenotype are less clear. EXPERIMENTAL
DESIGN: We conducted immunohistochemistry on 296 cases of breast cancer tissues using a variety of antibodies. On the basis of the clinical data, we conducted siRNA knockdown to study the role of ERα on ATM expression in breast cancer cell lines. Furthermore, we used antisense oligonucleotides against micro RNAs (miRNA) or miRNA overexpression plasmids to study the role of miR-18a and -106a on ATM expression. Finally we used in situ hybridization to assess miR-18a and -106a expression in breast cancer tissues.
RESULTS: We found that in ER-negative breast cancer tissues, expression of the ATM kinase, a critical DNA damage-response protein, is aberrantly upregulated. We also found that the locoregional recurrence rate after radiotherapy positively correlates with ATM expression. On the cellular level, we showed that ERα, but not ERβ, negatively regulates ATM expression. Furthermore, we identified that ERα activates miR-18a and -106a to downregulate ATM expression. We also showed that miR-18a and -106a were significantly underexpressed in ER-negative breast cancer tissues.
CONCLUSIONS: We reveal a novel mechanism involving ERα and miR-18a and -106a regulation of ATM in breast cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23857602      PMCID: PMC3778106          DOI: 10.1158/1078-0432.CCR-12-3700

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis.

Authors:  Pengxu Qian; Zehua Zuo; Zhengsheng Wu; Xianyi Meng; Gaopeng Li; Zhengzhou Wu; Weijie Zhang; Sheng Tan; Vijay Pandey; Yandan Yao; Puyue Wang; Liqing Zhao; Jun Wang; Qiang Wu; Erwei Song; Peter E Lobie; Zhinan Yin; Tao Zhu
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

2.  ATM activation in normal human tissues and testicular cancer.

Authors:  Jirina Bartkova; Christopher J Bakkenist; Ewa Rajpert-De Meyts; Niels E Skakkebaek; Maxwell Sehested; Jiri Lukas; Michael B Kastan; Jiri Bartek
Journal:  Cell Cycle       Date:  2005-06-13       Impact factor: 4.534

Review 3.  Dissecting the heterogeneity of triple-negative breast cancer.

Authors:  Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

4.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Authors:  Vassilis G Gorgoulis; Leandros-Vassilios F Vassiliou; Panagiotis Karakaidos; Panayotis Zacharatos; Athanassios Kotsinas; Triantafillos Liloglou; Monica Venere; Richard A Ditullio; Nikolaos G Kastrinakis; Brynn Levy; Dimitris Kletsas; Akihiro Yoneta; Meenhard Herlyn; Christos Kittas; Thanos D Halazonetis
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

Review 5.  Triple-negative breast cancer: therapeutic options.

Authors:  Susan Cleator; Wolfgang Heller; R Charles Coombes
Journal:  Lancet Oncol       Date:  2007-03       Impact factor: 41.316

6.  The ATM gene is a target for epigenetic silencing in locally advanced breast cancer.

Authors:  Quynh N Vo; Wan-Ju Kim; Luke Cvitanovic; Donald A Boudreau; David G Ginzinger; Kevin D Brown
Journal:  Oncogene       Date:  2004-12-16       Impact factor: 9.867

7.  Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.

Authors:  Maggie C U Cheang; K David Voduc; Dongsheng Tu; Shan Jiang; Samuel Leung; Stephen K Chia; Lois E Shepherd; Mark N Levine; Kathleen I Pritchard; Sherri Davies; Inge J Stijleman; Carole Davis; Mark T W Ebbert; Joel S Parker; Matthew J Ellis; Philip S Bernard; Charles M Perou; Torsten O Nielsen
Journal:  Clin Cancer Res       Date:  2012-02-20       Impact factor: 12.531

8.  Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells.

Authors:  Catia Morelli; Cecilia Garofalo; Monica Bartucci; Eva Surmacz
Journal:  Oncogene       Date:  2003-06-26       Impact factor: 9.867

9.  miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase.

Authors:  Libing Song; Chuyong Lin; Zhiqiang Wu; Hui Gong; Yong Zeng; Jueheng Wu; Mengfeng Li; Jun Li
Journal:  PLoS One       Date:  2011-09-27       Impact factor: 3.240

10.  Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel.

Authors:  George Fountzilas; Urania Dafni; Mattheos Bobos; Anna Batistatou; Vassiliki Kotoula; Helen Trihia; Vassiliki Malamou-Mitsi; Spyros Miliaras; Sofia Chrisafi; Savvas Papadopoulos; Maria Sotiropoulou; Theodoros Filippidis; Helen Gogas; Triantafyllia Koletsa; Dimitrios Bafaloukos; Despina Televantou; Konstantine T Kalogeras; Dimitrios Pectasides; Dimosthenis V Skarlos; Angelos Koutras; Meletios A Dimopoulos
Journal:  PLoS One       Date:  2012-06-05       Impact factor: 3.240

View more
  25 in total

1.  Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Authors:  Svasti Haricharan; Nindo Punturi; Purba Singh; Kimberly R Holloway; Meenakshi Anurag; Jacob Schmelz; Cheryl Schmidt; Jonathan T Lei; Vera Suman; Kelly Hunt; John A Olson; Jeremy Hoog; Shunqiang Li; Shixia Huang; Dean P Edwards; Shyam M Kavuri; Matthew N Bainbridge; Cynthia X Ma; Matthew J Ellis
Journal:  Cancer Discov       Date:  2017-08-11       Impact factor: 39.397

2.  Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.

Authors:  Yiqian Zhang; Chunling Jiang; Huilan Li; Feng Lv; Xiaoyan Li; Xiaolong Qian; Li Fu; Bo Xu; Xiaojing Guo
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA).

Authors:  Sara Y Kim; Tsutomu Kawaguchi; Li Yan; Jessica Young; Qianya Qi; Kazuaki Takabe
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

Review 4.  Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.

Authors:  Priya Bhardwaj; CheukMan C Au; Alberto Benito-Martin; Heta Ladumor; Sofya Oshchepkova; Ruth Moges; Kristy A Brown
Journal:  J Steroid Biochem Mol Biol       Date:  2019-03-06       Impact factor: 4.292

5.  Genomic-Epidemiologic Evidence That Estrogens Promote Breast Cancer Development.

Authors:  Fritz F Parl; Philip S Crooke; W Dale Plummer; William D Dupont
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-22       Impact factor: 4.254

6.  ATM may be a protective factor in endometrial carcinogenesis with the progesterone pathway.

Authors:  Weiwei Shan; Chao Wang; Zhenbo Zhang; Xuezhen Luo; Chengcheng Ning; Yinhua Yu; Youji Feng; Chao Gu; Xiaojun Chen
Journal:  Tumour Biol       Date:  2015-01-22

7.  Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.

Authors:  Carlos Marino Cabral Calvano Filho; Daniele Carvalho Calvano-Mendes; Kátia Cândido Carvalho; Gustavo Arantes Maciel; Marcos Desidério Ricci; Ana Paula Torres; José Roberto Filassi; Edmund Chada Baracat
Journal:  Tumour Biol       Date:  2014-05-09

8.  Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.

Authors:  Tarek M A Abdel-Fatah; Roslin Russell; Nada Albarakati; David J Maloney; Dorjbal Dorjsuren; Oscar M Rueda; Paul Moseley; Vivek Mohan; Hongmao Sun; Rachel Abbotts; Abhik Mukherjee; Devika Agarwal; Jennifer L Illuzzi; Ajit Jadhav; Anton Simeonov; Graham Ball; Stephen Chan; Carlos Caldas; Ian O Ellis; David M Wilson; Srinivasan Madhusudan
Journal:  Mol Oncol       Date:  2014-05-13       Impact factor: 6.603

Review 9.  The versatile functions of ATM kinase.

Authors:  Rebecca J Boohaker; Bo Xu
Journal:  Biomed J       Date:  2014 Jan-Feb       Impact factor: 4.910

10.  Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway.

Authors:  Yue-Can Zeng; Rui Xing; Jing Zeng; Ming Xue; Feng Chi; Yan Xin; Guo-Liang Fan; Hong-Mei Wang; Qiong-Yu Duan; Yu-Nan Sun; Nan Niu; Rong Wu
Journal:  Tumour Biol       Date:  2015-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.